Cointelegraph recently published an in-depth interview with LongeVC managing partner Sergey Jakimov on the launch of our second fund and the convergence of crypto and longevity biotech. The conversation covered Fund II’s $120 million strategy, its focus on early-to-mid stage therapeutics, diagnostics, and AI for drug discovery, and the novel ability for limited partners to make commitments in stablecoins.
Sergey also discussed how crypto’s evolution from short-term liquidity toward long-horizon investments aligns with longevity science, and how LongeVC is building a bridge between the two communities while maintaining institutional standards of compliance and conversion.
Read the full interview here.
Sergey also discussed how crypto’s evolution from short-term liquidity toward long-horizon investments aligns with longevity science, and how LongeVC is building a bridge between the two communities while maintaining institutional standards of compliance and conversion.
Read the full interview here.